Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick P J Phillips

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
BMJ (Clinical Research Ed.)|December 20, 2019
Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trialCharlotte R Brookfield, Patrick P J Phillips, Robert J Shorten
The New England Journal of Medicine|March 16, 2022
Four-Month Rifapentine Regimens for Tuberculosis. ReplyPatrick P J Phillips, Ekaterina V Kurbatova, Susan E Dorman
The Journal of Infectious Diseases|July 13, 2007
Biomarkers and surrogate end points in clinical trials of tuberculosis treatmentGeraint Rhys Davies, Patrick P J Phillips, Andrew J Nunn
Trials|September 24, 2025
Comparison of methods for identifying the optimal treatment duration in randomized trials for antibioticsSuzanne M Dufault, Brian H Aldana, Patrick P J Phillips
Advanced Drug Delivery Reviews|February 2, 2016
Challenges in the clinical assessment of novel tuberculosis drugsKelly E Dooley, Patrick P J Phillips, Payam Nahid, et al.
BMC Medical Research Methodology|November 16, 2013
A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosisDaniel J Bratton, Patrick P J Phillips, Mahesh K B Parmar
Tuberculosis (Edinburgh, Scotland)|August 25, 2010
Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cellsJasvir Dhillon, Koen Andries, Patrick P J Phillips, et al.
American Journal of Respiratory and Critical Care Medicine|August 4, 2021
Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical TrialsMarjorie Z Imperial, Patrick P J Phillips, Payam Nahid, et al.
Statistics in Medicine|December 1, 2023
A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studiesSuzanne M Dufault, Angela M Crook, Katie Rolfe, et al.
The Journal of Infectious Diseases|November 24, 2012
Reply to Dodd and ProschanPatrick P J Phillips, Daniel J Bratton, Andrew J Nunn, et al.
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
BMJ (Clinical Research Ed.)|December 20, 2019
Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trialCharlotte R Brookfield, Patrick P J Phillips, Robert J Shorten
The New England Journal of Medicine|March 16, 2022
Four-Month Rifapentine Regimens for Tuberculosis. ReplyPatrick P J Phillips, Ekaterina V Kurbatova, Susan E Dorman
The Journal of Infectious Diseases|July 13, 2007
Biomarkers and surrogate end points in clinical trials of tuberculosis treatmentGeraint Rhys Davies, Patrick P J Phillips, Andrew J Nunn
Trials|September 24, 2025
Comparison of methods for identifying the optimal treatment duration in randomized trials for antibioticsSuzanne M Dufault, Brian H Aldana, Patrick P J Phillips
Advanced Drug Delivery Reviews|February 2, 2016
Challenges in the clinical assessment of novel tuberculosis drugsKelly E Dooley, Patrick P J Phillips, Payam Nahid, et al.
BMC Medical Research Methodology|November 16, 2013
A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosisDaniel J Bratton, Patrick P J Phillips, Mahesh K B Parmar
Tuberculosis (Edinburgh, Scotland)|August 25, 2010
Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cellsJasvir Dhillon, Koen Andries, Patrick P J Phillips, et al.
American Journal of Respiratory and Critical Care Medicine|August 4, 2021
Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical TrialsMarjorie Z Imperial, Patrick P J Phillips, Payam Nahid, et al.
Statistics in Medicine|December 1, 2023
A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studiesSuzanne M Dufault, Angela M Crook, Katie Rolfe, et al.
The Journal of Infectious Diseases|November 24, 2012
Reply to Dodd and ProschanPatrick P J Phillips, Daniel J Bratton, Andrew J Nunn, et al.
Pageof 12